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Hepatitis B Virus: Transmission, Prevention,
Treatment and HIV Co-Infection
Hepatitis B Virus (HBV) infec-
tion is very common with over
350 million chronically infected
people worldwide including 1.25
million in the United States. The
incidence of acute HBV infec-
tion in the U.S. has declined
from 450,000 new infections per
year in the 1980s to 80,000 in
1999. Vaccination against HBV,
which has been available since
1982, is primarily responsible
for this decline.  Twenty to 80 %
of U. S. inmates have past or
active HBV infection, and 0.8 
1.4 % of inmates acquire HBV
while in prison (1, 2, 3).
HBV TRANSMISSION
High rates of HBV infection occur in people who have multiple sex partners, people who have per-
cutaneous blood exposures (those who share injecting drug equipment and patients on hemodialy-
sis) and health care or public safety workers who have frequent exposure to contaminated blood or
other infectious fluids. In the correctional environment, tattooing with contaminated needles may be
associated with HBV acquisition. Correctional officers may also be at increased risk of HBV infection
because of exposure to inmates blood and other body fluids during the course of their work.
Household contacts of those with acute or chronic HBV infection and infants of mothers with chron-
ic HBV infection are also at risk for acquiring HBV. In prisons, cellmates are analogous to household
contacts. Transfusion as a cause of acute Hepatitis B (and Hepatitis C) has decreased dramatically
in the past two decades since screening has become increasingly sensitive and more cost-effective.
Since HIV and HBV have similar modes of transmission, coinfection is quite common. 
ACUTE HEPATITIS B INFECTION
The clinical, serologic, and immunologic responses following infection with HBV infection have been
well-described. Only 25 - 50 % of cases of acute HBV infection are symptomatic; the remainder are
asymptomatic or are associated with inconsequential symptoms. Following an incubation period that
varies from one week to six months, symptoms of the pre-icteric phase include malaise, weakness,
anorexia, nausea, vomiting, and right upper quadrant pain. Oddly, these symptoms begin to abate
during the icteric phase (jaundice) that persists for approximately three weeks.  The hepatic transam-
inases peak, and then begin to decline during this time period. During the convalescent phase, which
may last for up to six months, symptoms completely resolve (4).
Following exposure to HBV, a well-defined immunologic response results in resolution of infection
and protective immunity.  The first serologic marker of HBV infection to appear is Hepatitis B surface
antigen (HBsAg), a protein on the surface of the
virus.  This antigen usually persists in serum
throughout the period of clinical illness, and is
commonly used to diagnose acute HBV infection.
During convalescence, the disappearance of
HBsAg and the appearance of anti-HBsAg
(HBsAb) mark resolution of the acute infection. In
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acute HBV infection, resolution occurs in
six months or less.  In addition, there are
other serologic and immunologic markers
of acute HBV infection. Hepatitis B core
antibody (anti-HBc), an antibody directed
against the nucleocapsid of HBV generally
appears at approximately the same time as
HBsAb.  HBc IgM develops initially and is
eventually replaced by HBc IgG.  In the
minority of cases of acute HBV infection
that come to clinical attention, HBsAb
develops prior to the icteric phase.  Since
HBsAg disappears when HBsAb develops,
HBsAg cannot be used to make the diag-
nosis of acute HBV infection in these rare
instances. Instead, HBc IgM must be used
to confirm the diagnosis.  Another viral pro-
tein, Hepatitis B e antigen (HBeAg) and its
corresponding antibody (HBeAb) follow a
similar course to HBsAg and HBsAb, but
these markers are rarely used for diagnosis
of acute HBV infections.  Seroconversion of
HBeAg to HBeAb is associated with a
decline in viral replication and disease
severity (4).  Figure 1 summarizes the sero-
logic and immunologic responses encoun-
tered in acute HBV infection. 
CHRONIC HBV INFECTION
In approximately 10 % of new infections,
HBsAg persists in the serum for greater
than six months, and chronic HBV infection
is established. Individuals with persistent
HBsAg are often called chronic carriers.
Prior infection with HIV increases the likeli-
hood that chronic HBV infection will occur.  
The course of chronic HBV infection is
characterized by the persistence of HbsAg
in the serum and the failure to develop
HBsAb, which provides protective immuni-
ty. In chronic HBV infection, the persistence
of HBeAg (and failure to develop HBeAb) is
associated with greater viral replication,
higher HBV DNA in the serum, and more
severe disease. 
In the liver, chronic HBV infection causes
inflammation, hepatic cell necrosis, and cir-
rhosis in approximately 50% of those
infected.  Hepatic failure and/or hepatocel-
lular carcinoma occur in a significant num-
ber of patients.  Chronic HBV infection is
characterized by periods of disease activity
and periods of disease quiesence. Serum
transaminase levels increase with
increased disease activity and may
decrease to within normal limits during peri-
ods of disease quiesence. Serum quantita-
tive HBV DNA levels also vary with disease
activity.  Clinically, symptoms may wax and
wane with disease activity and may include
fatigue, right upper quadrant discomfort,
jaundice, and mild fever.  Some patients
are asymptomatic (4). Figure 2 summa-
rizes the serologic and immunologic course
of chronic HBV infection.
TREATMENT OF HBV
INFECTION
There is no specific therapy for acute viral
hepatitis. Supportive therapy including
intravenous fluids, antiemetics, mild anal-
gesia, and antipyretics may be necessary
in some cases.  It is prudent to stop poten-
tially hepatotoxic medications, including
antiretroviral drugs, until transaminase lev-
els approach normal values.  Acute fulmi-
nant hepatitis and death occur in 0.5  1 %
of cases of acute HBV infection.
Treatment and monitoring of patients with
chronic HBV infection should be carried out
by providers who are experienced in man-
aging chronic HBV.  Prior to treatment, liver
biopsy is generally performed.  Patients
with decompensated liver failure or severe
cirrhosis should not be treated for chronic
HBV infection because treatment in these
cases may actually lead to hepatic failure.
Side effects are commonly encountered
during treatment.
Interferon alpha 2b was the first drug
approved by the United States Food and
Drug Administration (U.S.F.D.A.) for the
treatment of chronic HBV infection. The
recommended treatment course is 5 million
units injected subcutaneously daily or 10
million units injected subcutaneously three
times per week for 16 weeks.
Approximately 40 % of those receiving this
treatment will have a successful outcome,
which is defined as seroconversion of
HBeAg (i.e., loss of e antigen and acquisi-
tion of HBeAb).  It appears that treatment
with interferon reduces the occurrence of
cirrhosis, hepatic failure, and hepatocellular
carcinoma.  Co-infection with HIV is a pre-
dictor of poor response to interferon treat-
ment. 
Lamivudine (Epivir-HBV tablets or oral
solution) has also been approved by the
U.S.F.D.A. for the treatment of chronic HBV
infection. The recommended dosage is 100
mg qd.  The optimal duration of treatment is
unclear, although most studies have
involved one year of treatment.
Approximately 15 % of patients treated with
lamivudine have seroconversion of HBeAg.
HBV DNA disappears during treatment, but
usually becomes detectable again when
treatment is stopped.  ALT also decreases
during treatment, but may rebound to two
or three times the baseline value after treat-
ment is stopped. Lamivudine-resistant HBV
have emerged during treatment with
lamivudine.  It is unclear whether patients
have a decrease in clinical endpoints such
as cirrhosis, liver failure, and hepatocellular
carcinoma following treatment with lamivu-
dine.
Hepatic transplantation is an option for
patients with end-stage liver disease sec-
ondary to chronic HBV infection.
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Figure 2. Progression to Chronic Hepatitis B Virus Infection
Acute
(6 months)
Titer
Chronic
(Years)
anti-HBeHBeAg
HBsAg
Total anti-HBc
Weeks After Exposure
Years0  4   8  12  16 20 24 28 32 36      52
lg M anti-HBc
Figure 3. Guide to postexposure immunoprophylaxis with HBIG and HBV Vaccine
Type of Exposure
Perinatal
Sexual  acute infection
Sexual  chronic carrier
Household contact  chronic carrier
Household contact  acute case
Household contact  acute case, 
known exposure
Infant (< 12 months)  acute case in 
primary caregiver
Inadvertant percutaneous/permucosal
Post Exposure Prophylaxis
Vaccination + HBIG
HBIG +/- vaccination
Vaccination
Vaccination
None unless known exposure
HBIG +/- vaccine
HBIG + vaccination
Vaccination +/- HBIG
Dear Colleagues,
As this edition of HEPP News went to press, we were encouraged by the news that the United
Nations General Assembly has adopted a "Declaration of Commitment on HIV/AIDS".  Although
significant concessions were made in the drafting of this document, this does mark the first time
that the General Assembly has convened solely to confront an infectious disease.  This declara-
tion sets (non-binding) time frames within which member nations are to expand access to HIV
testing, prevention tools such as male and female condoms, disposable syringes, prenatal care,
and perinatal measures to decrease vertical transmission of HIV.  In addition, the declaration calls
for the development of improved health care delivery systems, access to reduced cost medica-
tions, measures to promote gender equality and to protect those living with HIV/AIDS, and fund-
ing for low and middle income countries to accomplish these goals. 
Although we are now twenty years into the HIV epidemic, it is hoped that the increased spotlight
on this issue brought about by the United Nations declaration will mark a turning point in the fight
against AIDS and help to control the explosive growth of HIV worldwide. 
In this issue, HEPP News senior advisor David Paar focuses on the diagnosis, treatment, and
prevention of Hepatitis B.  By vaccinating our patients and colleagues, we in correctional health
have the opportunity to prevent cancer, cirrhosis, and further transmission of this potentially dev-
astating virus.  Dr. Paar also provides an update on the Texas Department of Corrections four
years of experience with telemedicine. This months HEPPigram provides an algorithm for the
management of abnormal liver function tests, while Dr. Nick Capozzoli draws upon his experience
as a correctional neurologist to review peripheral neuropathy. 
After reviewing this issue, readers should know more about the management of Hepatitis B, be
able to discuss the use of telemedicine in the delivery of HIV care within corrections, and have a
better understanding of the diagnosis and management of peripheral neuropathy.
This month, we welcome Rebecca Nerenberg as the new managing editor for HEPP News.   As
always, we encourage your suggestions for future HEPP News topics!  
Sincerely,
Joseph Bick   
Letter from the Editor
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4PREVENTING HBV INFECTION
Avoiding contact with contaminated blood by
using universal precautions is the only way
to be 100% protected against HBV infection.
However, it has been shown that immuniza-
tion with recombinant HBV vaccine is an
effective means of preventing infection.   The
Immunization Practices Advisory Committee
(ACIP) of the Centers for Disease Control
and Prevention recommends that all new-
borns, children, and adolescents be immu-
nized to help eliminate HBV in the United
States. Adults in high risk groups should be
vaccinated but vaccination of all adults is not
recommended at this time. In addition, older
adults are at lower risk. One hundred ten
other countries have a similar policy. 
When vaccination is required, Recombivax
HB and Engerix-B are two preparations that
are available in the United States.  The most
common vaccination schedule is three intra-
muscular injections with the second and third
doses being administered one and six
months after the first; Engerix-B has also
been licensed for a series of four injections
given at 0, 1, 2, and 12 months (2).
When an exposure to HBV occurs in a sus-
ceptible individual, postexposure prophylaxis
with Hepatitis B Immune Globulin (HBIG)
and/or vaccination is recommended in most
cases. Figure 3 is a guide to postexposure
prophylaxis (2). Available Hepatitis vaccines
are presented in figure 4.
HBV AND HIV COINFECTION
HIV and HBV interact when they occur in the
same host, as previously noted (5,6). Like
any other infection that occurs in HIV positive
individuals, HBV infection activates the
immune system leading to proliferation of
CD4 cells which enhances HIV replication
and increased plasma HIV RNA (viral load).
In addition to this indirect effect on HIV repli-
cation, HBV proteins directly stimulate HIV
replication.  Theoretically, this results in more
rapid HIV disease progression if the increase
in HIV replication is sustained for a signifi-
cant length of time.  However, the literature
does not consistently support the presump-
tion that HIV progression is accelerated by
concomitant HBV infection. It does appear
however that HIV infection may accelerate
the progression to hepatic failure and hepat-
ic failure-related deaths in patients with
chronic HBV infection (6).
In coinfected patients, most published
reports indicate that serum HBV DNA is high-
er, serum alanine aminotransferase levels
(ALT) are lower, and liver inflammation and
cirrhosis are less than in patients with HBV
alone.   This is not an unexpected finding
since cell-mediated-immunity (CMI), the pri-
mary factor in eliminating HBV from infected
hepatocytes, is impaired by HIV infection.  In
studies that demonstrated the efficacy of
interferon-alpha 2b for chronic HBV infection,
HIV negative participants with high serum
HBV levels, low serum ALT levels, and mild
histopathologic scores on liver biopsy were
less likely to respond to interferon treatment
for chronic HBV infection than participants
who had lower HBV DNA levels, higher ALT
levels, and more severe inflammation on
liver biopsy.  Given this fact, it is not surpris-
ing that patients with chronic HBV and HIV
coinfection are less likely to respond to
interferon treatment for chronic HBV infec-
tion.  Patients with chronic HBV and HIV are
more likely to have clinically significant
hepatotoxicity when placed on antiretroviral
agents in general and may have increased
incidence and severity of indinavir-
associated hyperbilirubinemia (7). 
When lamivudine is included in an antiretro-
viral regimen in patients with HIV and HBV
coinfection, HBV viral replication is often
reduced to nondetectable for the duration of
lamivudine treatment. Whether this finding is
associated with a more favorable hepatic
outcome is unclear at the present time.
CORRECTIONAL HEPATITIS
The Centers for Disease Control (CDC), con-
vened a meeting this Spring on Hepatitis in
correctional settings that was attended by
more than 100 federal and state correctional
healthcare professionals. Representatives of
correctional organizations (ACA, NCCHC)
and representatives from federal agencies
such as the OSHA and NIOSH also attended
the meeting. CDC speakers discussed the
need to expand HBV and HCV interventions,
including screening, education, vaccination,
and treatment of chronic Hepatitis in correc-
tional settings. Guidelines for HCV and HBV
management will be issued by the CDC as a
supplement to the MMWR in the fall. While
sources of funding for increased Hepatitis
interventions in corrections were not specifi-
cally addressed, participants discussed
promoting correctional settings as outposts
for public health activities may ultimately
lead to increased financial support from
federal and state sources for correctional
treatment initiatives. 
*Speakers Bureau: Roche Pharmaceuticals
REFERENCES:
1. Sylvan S.  WHO spearheads global initiative to eradicate hepatitis B:
Lakartidningen 2000 August 30;97(35):3738-40.
2. Hepatitis B Virus:  A Comprehensive Strategy for Eliminating
Transmission in the United States Through Universal Childhood
Vaccination:  Recommendations of the Immunization Practices Advisory
Committee (ACIP).  MMWR November 1991;40(RR-13); 1-19.
3. Bader, TF:  Hepatitis B in prisons.  Biomed Pharmacother
1986;40(7):248-51. 
4. Hoofnagle Jay H., MD, and Schafer, Daniel F., MD.  Serologic Markers fo
Hepatitis B Virus Infection; Seminars in Liver Disease Vol. 6 No. 1, 1998.
5. Hadler SC, Judson FN, O’Malley PM, et al: Outcome of hepatitis B virus
infection in homosexual men and its relation to prior human immunodefi-
ciency virus infection.  J Infect Dis 163:454-459, 1991.
6. A.N.B. McNair, M.A., M.R.C.P.k, Janice Main, M.D., and H.C. Thomas,
M.D., Ph.D.:  Interactions of the Human Immunodeficiency Virus and the
Hepatotropic Viruses.  Seminars in Liver Disease - Vol. 12, No. 2, 1992.
7. Gisolf EH, Dreezen D, Danner SA, Weel JL, Weverling GJ; Prometheus
Study Group.  Risk factor for hepatotoxicity in HIV-1infected patients receiv-
ing ritonavir and saquinavir with or without stavudine.  Clin Infect Dis 2000
Nov;31(5):1234-9.
Hepatitis B...
(continued from page 2)
June/July 2001     Volume 4, Issues 6&7 visit HEPP News online at www.hivcorrections.org
Figure 4. Hepatitis Vaccines
Hepatitis A (HAV) Vaccines
G Two HAV vaccines available perform
equally well; both are based on an 
inactivated virus
G Two doses are recommended, the sec-
ond dose given 6-12 months after the first
G Havrix: manufactured by Glaxo Smith
Kline
G VAQTA: manufactured by Merck, there
is a pediatric version available for use 
up to 18 years of age
G Twinrix: a combination HAV and HBV
vaccine consisting of inactivated HAV 
and genetically derived HBsAg is 
currently undergoing trials
Hepatitis B (HBV) Vaccines
G There are three HBV vaccines available;
all are recombinant (genetically 
engineered) HBsAg vaccines
G The vaccine schedule involves three
intramuscular injections at 0, 1, and 
6 months.
G Engerix-B: manufactured by Glaxo Smith
Kline
G Recombivax-HB: manufactured by Merck
G Comvax: manufactued by Merck, 
combination Haemophilus B conjugate 
and HBV vaccine
http://www.who.int/vaccines/intermediate/hepatitisa.htm
http://www.cdc.gov/ncidod/diseases/hepatitis/a/index.htm
http://www.who.int/vaccines/intermediate/hepatitisb.htm
Spotlight: Telemedicine in Clinical Practice
An Update From The Texas Department of Criminal Justice (TDCJ)
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Telemedicine was introduced in the U.S. in the late 1950s using the
limited technology of the time, and despite enormous technological
advances that have made remote real-time audiovisual communica-
tion, examination, and robotically controlled surgical procedures
possible, the practical application of telemedicine remains limited.
Provider acceptance remains a significant factor in the limited use of
telemedicine, which is a particular concern for HIV-treating physi-
cians since a satisfactory/trusting patient/provider relationship has
been identified as one of the most significant factors in predicting
adherence to antiretroviral therapy (1).  In prisons in particular,
where there are so many other potential barriers to effective HIV
care, introducing a new and untried technology may seem particu-
larly imprudent to providers. 
Since nonadherence is the primary reason for antiretroviral failure
and the development of viral resistance (and cross-resistance) (1) to
the growing, but still limited number of antiretroviral agents, it is
imperative that the effectiveness of new treatment modalities be
questioned.  Unfortunately, clinically significant medical outcome
studies on the effectiveness of telemedicine in delivering HIV care
have not been reported. Additional concerns include the rapid
obsolesence of telemedicine equipment, and some providers have
had difficulty furnishing complete paper record copies to telemedi-
cine receiving sites. However, implementation of electronic health
records is on the rise and should circumvent the latter issue. Another
significant factor may be the substantial cost of T-1 lines, even if in
fractional use. Recent dissemination of complementary, lower cost
technologies may decrease telemedicine costs. Some published
reports have demonstrated that telemedicine has reduced correc-
tional health care costs, which is attributed to a reduction in security
and other travel-associated costs incurred when incarcerated
patients are transported from remote sites to specialists (2).
In late 1997, TDCJ Correctional Managed Care developed and
implemented a telemedicine program aimed at providing specialty
care from a site on the The University of Texas Medical Branch at
Galveston (UTMB) campus to patients incarcerated in over 90 prison
units in eastern Texas.  For HIV care, as well as other specialty care,
this was a major shift in health care delivery since HIV positive
offenders had always been transported to Hospital Galveston (HG)
for HIV care and participation in clinical trials at UTMB. 
Despite the fact that a busy eight hour/week telemedicine clinic with
an average census of 35  40 patients per session has been estab-
lished, an onsite HG HIV Clinic has been maintained to deliver
health care to patients for whom telemedicine has been deemed
inadequate.  It is the clinical judgment of the telemedicine provider
to determine whether  telemedicine is inadequate.  There are no pre-
established criteria.  The usual reasons for requesting an onsite visit
rather than a telemedicine follow up are that the provider does not
feel that (s)he is "connecting" with the patient, there is a physical
exam finding that cannot be evaluated using telemedicine, or the
patients presentation is too complicated and needs extra attention
in an onsite visit.  Failure for a patient to achieve a nondetectable
virus load is not a reason for an onsite visit as long as the provider
feels that (s)he is adequately communicating with the patient and the
patient does not have a physical exam finding that requires a hands-
on exam. Additionally, UTMBs AIDS Care and Clinical Research
Program maintains a clinical trials program for HIV+ prisoners, and
those who wish to be screened and followed on clinical trials must
travel to Galveston for initial screening and  study-related follow up.
The introduction of telemedicine provided an opportunity to compare
telemedicine consultation with on-site (HG) consultation in the HIV
care program, and to determine whether HIV care (both telemedi-
cine and HG on-site care) was comparable to local community stan-
dards. This study was carried out by conducting a chart review.
As part of the assessment, we asked the question, is there a differ-
ence in the proportion of patients with a nondetectable virus load
seen in the community clinic staffed by the same providers who staff
the TDCJ HIV clinics.  A random sample of charts of patients seen
between September 2000 and March 2001 was selected from the
Community Clinic (unincarcerated patients), TDCJ Telemedicine
Clinic, TDCJ HG Clinic (TDCJ patients for whom telemedicine has
been deemed inadequate), and TDCJ Research Clinic (HG clinic for
incarcerated patients participating in clinical trials) and were
reviewed for pertinent clinical information including the proportion of
patients receiving antiretroviral treatment and  most recent virus load
determination.  Since incarcerated patients may attend any of the
three TDCJ clinics depending on clinical circumstances or clinical
trial participation, charts were included for review only if the last
three visits were conducted in the same clinic, or if there were only
two documented visits, both must have occurred in the same clinic
(See Figure 2 above).
by David Paar, Associate Professor of Medicine, Director, HIV Care/TDCJ Correctional Managed Care
Continued on page 6
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Figure 2. Results of Randomly Selected Chart 
Review to Internal Audit Purposes
Unincarcerated
HIV+ Patients
Community
964
75
90 %
49 %
TDCJ HIV+
Patients
Telemedicine
1587
84
83 %
60 %
HG
1068
72
92 %
42 %
HG
Research
296
63
97 %
76 %
Clinic
# appointments
# charts
reviewed
% receiving
ART
% non-
detectable VL*
*Results compared with one way ANOVA and binomial confidence limits
ART  antiretroviral therapy
VL  virus load (either <50 or < 400 depending on which determination was
most recently performed)
HG = Hospital Galveston 
HG Research = Clinial trial study group at HG
Figure1. Clinic Visits
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
1994     1995     1996     1997     1998     1999     2000     2001
Visits Hospital
Galveston
Visits 
Telemedicine
6Most patients were seen multiple
times during the six-month period
covering this chart review.
Therefore, the approximate num-
ber of patients seen in each clinic
can be determined by dividing the
number of appointments by three.
The number of charts reviewed
represents a 15  20% sample of
the total number of patients seen
in each clinic.
A one way analysis of variation
(ANOVA) and binomial confidence
limits analyses were performed
in order to analyze the viral
load response data. The results
showed that a significant differ-
ence cannot be detected between
the viral load responses in
Group 1 (Community), Group 2
(Telemedicine), Group 3 (Hospital
Galveston), and Group 4 (HG
Research).  Although there was a
trend towards a significant differ-
ence in the HG Research Group,
this reached borderline signifi-
cance in the binomial confidence
limits analysis only. These results
are limited. 
This chart review was not a scien-
tifically designed study; it was
done as part of an internal audit
program to determine how to
improve HIV care in the TDCJ.
Patients were not matched for dis-
ease stage, sex, race, anti-
retroviral history, or other factors,
which might influence viral load
response, but the samples were
randomly selected.  
The next step is to conduct an
appropriately powered, prospec-
tively-designed trial that considers
variables that determine the over-
all effectiveness of HIV health care
delivery. 
Yet, some preliminary conclusions can be drawn. First, this informa-
tion agrees with other reports (3, 4) indicating that while approxi-
mately 80% of clinical trial participants (HG Research) have a
reduction in virus load to below the levels of detection, the respons-
es in clinical practice are more variable. This finding is expected
since relatively well patients who are less likely to have drug-
resistant viruses and who have been selected for their ability to
adhere to medical treatment should have the best response to
investigational antiretroviral regimens. Second, the viral load
responses of patients seen by ACCRP HIV Specialists are similar
whether the patients are seen by telemedicine or in traditional face-
to-face encounters. These preliminary results are very encouraging.
We interpret the results to reflect our experience that telemedicine
can result in the type of patient/provider relationship that translates
into adherence and reduction in viral load to nondetectable levels in
a select group of patients.
References:
1.  HIV Treatment Guidelines available at http://www.hivatis.org.
2.  Paar, David, Telemedicine in Practice: Texas Department of Criminal Justice, HEPP News, May 2000.
3. S. Guerin, L. Meyer, I. Thodorou, F. Boufassa, M. Magierowska, C. Goujard, C. Rouzioux, P. Debre, J.F. Dlefraissy, and SEROCO/HEMOCO Study Group.
Deletion and Response to HAART in HIV-1-Infected Patients.  7th Conference on Retroviruses and Opportunistic Infections.  Abstract # 452, 2000.
4. BY Nguyen, DW Haas, C Ramirez-Ronda, MA Thompson, J Gallant, J Currier, D Paar, C White, A Collier, D Mehrotra, M Chung, C Harvery, J Chodakewitz,
Thirty Two Week Follow-up of Indinavir Sulfate (IDV) Administered Q8 Hours (H) Versus Q12 H in Combination With Zidovudine (ZDV) and Lamivudine (3TC):
The 5th Conference on Retroviruses and Opportunistic Infections.  Abstract # 374, 1998.
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HEPPigram: Elevated Liver Function Test
Is the patient on medication that might cause this condition? 
i.e., Antiretroviral, TB, and Psych medications
Yes.
Are these medications the likely cause of
the abnormal LFTs?
No.
Consider the causes:
Is there evidence for acute or chronic
viral hepatitis infection determined by the
presence of:
G HCV Ab?
G HAV IgM?
G HBV sAg?Yes
Refer to
Gastroenterologist or
infectious disease
specialist for evalua-
tion; consider other
viral hepatitides,
nonalcoholic 
No
Information
available
Information NOT
available
Screen for
HAV, HBV, HCV
AST/ALT>4X-5X 
Consider stopping 
medication 
Re-evaluate in 
2-3 days
Consider other 
causes
AST/ALT<4X-5X 
Normal 
(monitor closely)
Acute viral hepatitis may require no
treatment or may require sympto-
matic relief with antiemetics, 
intravenous fluids, and other mea-
sures. Treatment of chronic active
HBV and HCV  and of associated
complications usually requires the
expertise of a gastroenterologist or
infectious disease specialist.
Yes, to one or more. No
7Neurologic disease is frequently asso-
ciated with HIV infection. Both the
central nervous system (CNS) and
the peripheral nervous system (PNS)
may be affected. The causes of neu-
rological disease are various: autoim-
mune reactions due to immune dis-
regulation; opportunistic infections
(OIs); metabolic and nutritional derangement
due to or associated with AIDS; the direct attack
on nerve tissue by HIV; and the toxic effects of
drugs used to treat HIV and OIs.
The most common neurologic problem in HIV
infection is peripheral neuropathy (PN), which
involves lesions of the PNS. The major form of
PN in HIV disease is distal symmetric polyneu-
ropathy (DSPN), which has been reported to
occur in about a third of patients with AIDS(1).
Several other PN types are associated with HIV
disease, mainly acute and chronic inflammatory demyelinating
polyradiculoneuropathies (Guillain-Barre-like diseases), mononeuropa-
thy multiplex, and multifocal motor neuropathy.  These diseases may
be quite serious and life threatening. It is important to recognize them,
but they are rare and occur in about 1% of AIDS patients.
DSPN is a "pattern recognition" disease involving a distal and sym-
metric numbness and/or dysesthesia, the famous "stocking and glove"
distribution. This pattern results from the presumed mechanism of
polyneuropathy, in which there is believed to be a systemic attack upon
the nerves. Nerve repair is under the direction of the nerve cell body,
which contains the nucleus and cell machinery.
In theory, the clinical diagnosis of DSPN is straightforward for any com-
petent examiner.  A "directed" neurologic exam for suspected DSPN is
simple and should be performed by the provider when the patients
complaints are consistent with DSPN, i.e., numbness and or pain (usu-
ally described as burning, tingling, or "pins and needles") involving the
distal extremities. The toes and feet are usually affected first, and as
the disease progresses the height of the "stocking" will rise. When the
symptoms reach the upper portions of the legs, the fingers and hands
may be affected. There may or may not be weakness of the distal
extremities. DSPN seems to affect primarily sensory nerves, but there
may be some weakness, most often described as "clumsiness."
Patients may complain that they can no longer cross their toes, or that
their fingers are clumsy when they try to perform fine manipulations,
like buttoning a shirt.
The exam consists first of "subjective" sensory testing, where the
examiner uses a safety pin, 128 Hz tuning fork, and cotton swabs to
assess vibration, thermal, light touch, and pain sensation. The tuning
fork is used to evaluate vibration and thermal sensation. In order to test
the latter, the weighted end of the fork is touched to the skin and the
patient is asked whether it feels hot or cold. In DSPN one would expect
the patient to report a distal and symmetric loss of perception of the
various modalities. It is important to check all four modalities.
Next, the "objective" portion of the exam consists of checking the reflex
pattern and muscle bulk and strength. In DSPN, one would expect a
diminution or loss of the ankle jerk reflexes. The most common muscle
bulk abnormality in DSPN is a loss of the extensor digitalis brevis mus-
cles and "high arches" (a pes cavus/talipes deformity), as assessed by
physical inspection. Another objective sign of DSPN is atrophic skin
change, particularly a significant loss of hair from the distal extremities.
Hair is usually present over the great toe and the ankle area.
When necessary, the diagnosis of DSPN can be confirmed by elec-
tromyelography (EMG) and nerve conduction velocities (NCVs or
NCSs). My screening protocol for DSPN consists of checking the sural
sensory, posterior tibial motor, posterior tibial F-waves, and H-reflex
waveforms. Needle EMG is performed if there is a suspicion of radicu-
lopathy or axonopathy.
In my non-prison practice I have found that my clinical diagnosis of
DSPN is supported by EMG/NCS testing 90% of the time.  In my prison
practice my clinical diagnosis is supported by the results of EMG/NCS
only 33% of the time.  In other words, about 2/3 of my prison patients
who present with "classic" DSPN are normal on all tests.
I have wondered why the clinical impression should be so discordant
with the electrophysiological results in my prison patients. One thing
that impresses me is that there is a higher rate of Hepatitis C coinfec-
tion among HIV+ patients in the prison than in the non-prison setting. It
is possible that Hepatitis C coinfection contributes to the symptoms that
mimic DSPN. Chronic hepatitis of all types is associated with pruritis
and burning/tingling dysesthesiae of the extremities. Erythromelalgia is
the specific term for these dysesthesiae. The discomfort of erythrome-
lagia is due to the irritation of dermal nerve endings by circulating
vasoactive substances and toxins, rather than due to actual nerve
damage.
Additionally, one must consider the reality that incarcerated patients
have a high rate of substance dependence and may be influenced by
secondary gain, may be consciously or subconsciously fabricating
and/or amplifying symptoms. A drug addict stuck in prison may be
seeking narcotics or other drugs for purposes other than pain control. 
In summary, DSPN is common in patients who have HIV infection.  In
the non-prison setting, this diagnosis can usually be confirmed by tak-
ing an appropriate history and performing a directed neurological
examination.  In correctional medicine, the diagnosis may be compli-
cated by coinfections such as HCV which may cause symptoms that
mimic DSPN and drug-seeking behaviors among a population who
have a high rate of substance dependence. In correctional medicine, if
the diagnosis of DSPN is to be made on purely clinical grounds, it must
be based on objective abnormalities, such as muscle wasting, loss of
deep tendon reflexes, and atrophic skin changes. If these abnormali-
ties are not present, it may be necessary to confirm or exclude the
diagnosis with the use of electrophysiologic testing. A good "screening
protocol" for DSPN includes testing sural sensory, posterior tibial motor
and F-wave studies, and the H-reflexes. If these are completely nor-
mal, one can exclude any significant polyneuropathy.
*Nothing to disclose
1. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Arch Neurol. 1988; 45: 945-948. 
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Peripheral Neuropathy Treatment
Drug Treatments
G Nortriptyline 10 mg hs: increase dose
by 10mg q 5 days to a maximum of 75
mg hs or 10-20mg po tid
G Neurotin (gabapentin): 
300-800 mg po tid
G Ibuprofen 600-800 mg tid
G Topical: Capsaicin-containing ointments
(Zostrix, etc.) For topical application;
Lidocaine ointment 20-30% for topical use
G Alternatives: Phenytoin 200-400mg/d
and crabmazepine 200-400 mg po bid
Related Comments
G Other tricyclics commonly used:
amitriptyline, desipramine, or imipramine
G Capsaicin is often not well tolerated
G Mexiletene: inferior to amitriptyline in
ACTG 242 and appeared no better than a
placebo.  Capsaicin ointment treatment dis-
appointing.
G One report of 2 patients suggests
response to HAART (Lancet 1998;
352:1906).
G A controlled trial of acupuncture failed to
show any benefit (JAMA 1998; 280: 1590).
G Nucleosides commonly implicated, 
Contributed by Nicholas J. Capozzoli, MD, DABPN*, Physician and Surgeon in the California Department of Corrections 
at the California Medical Center at Vacaville and San Quentin State Prison
Table adapted from Bartlett JG, and Gallant
JE.  2000-2001 Medical Management of HIV
Infection, p.134.
United States Conference on
AIDS (USCA) 2001
September 13-16, 2001 
Fontainebleau Hilton Resort and
Towers/ Miami Beach, Florida
For details, see
http://www.nmac.org/
usca2001/home.htm
Pre-conference symposium on
HIV and Hepatitis in Corrections
sponsored by NMAC and 
HEPP News
email: info@nmac.org
call: 202.483.6622 
Fee: June 15-August 21:
$375/members; 
$450/nonmembers; 
On-site: $550
Infectious Disease Society of
America (IDSA): 39th Annual
Meeting
October 2528, 2001
San Francisco, California
Late-breaker abstract deadline:
August 20, 2001
Discounted registration deadline:
July 30, 2001
Write: 99 Canal Center Plaza,
Suite 210 Alexandria, VA 22314
Fax: 703.299.0204
Visit: http://www.idsociety.org
Save the 
Dates
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Resources & Websites
Hepatitis Websites:
July 2001 Hepatitis C Virus (HCV) Advocate
http://www.hcvadvocate.org
CDCs Hepatitis webpage
http://www.cdc.gov/ncidod/diseases/hepatitis/index.html
NIHs National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK)
http://www.niddk.nih.gov
The American Liver Foundation
http://www.liverfoundation.org
Canadian Hepatitis Info site
http://www.hepnet.com
HIV and Hepatits C Coinfection: ATIS
http://www.hivatis.org/hepatitisC.html
HIV Treatment Websites: 
HRSA Releases Treatment Guide for Women
http://hab.hrsa.gov/womencare.htm
Medscape HIV/AIDS
http://hiv.medscape.com
Hepatitis C: A Correctional-Public Health Opportunity
http://www.medscape.com/Medscape/ID/journal/2001/v03.n03/mid0
614.groo/mid0614.groo-01.html
HIV Insite:
http://hivinsite.ucsf.edu
AEGiS: The largest HIV/AIDS resource on the Internet
http://www.aegis.com
Neuropathy Websites:
The Neuropathy Association
http://www.neuropathy.org/index.asp
Medicine Net
http://www.medicinenet.com
AIDS Treatment News: Neuropathy
http://www.immunet.org/immunet/atn.nsf/page/a-250-09
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Substituting Non-Nucleoside Drugs for
Protease Inhibitors May Result in Lower
Lipid Levels
Protease inihibitors (PIs) have been linked to
certain side effects inlcuding the development
of high levels of lipids (triglycerides and cho-
lesterol) in the blood. Switching patients to a
non-nucleoside based drug regimen (using
Nevirapine or Efavirenz) has been a common
strategy used by physicians to counter this
problem. However, Swiss researchers have
recently found that 38% of patients continued
to have high cholesterol levels once their med-
ication was switched. When the patient was
originally taking the PI Ritonavir, the switch to
Efavirenz was more likely to decrease the
triglyceride levels. Patients originally on other
PIs who switched to Efavirenz had little or no
change in lipid levels. Authors suggest
clinicians should keep this in mind when
considering changes in a patients regimen. In
another study released this week, Viramune
(Nevirapine) did seem to be associated with
lower lipid levels. HIV care providers should be
aware that the "jury is still out" on the effect of
NNRTIs vs PIs on lipid levels. (J AIDS 2001; 26
(4): 389-391.) 
HIV Drug Therapies: Failures Reported
Physicians in Pima County, Arizona are begin-
ning to see an increase in AIDS-related deaths
for the first time since the advent of HAART in
1995; the number of AIDS-related deaths this
year is expected to double. Washington State
is also seeing an increase in AIDS cases for
the year 2000, the first increase in nine years.
The percentage of women and minorities with
AIDS is also increasing. These increases may
be attributable to lack of access to treatment
and the beginning of failure of the triple-drug
cocktail which has become the standard regi-
men for HIV infection. Health officials in the
United Kingdom are seeing a similar phenom-
enon, with as many as 25% to 27% of HIV
patients exhibiting resistance to one or more
antiretroviral drugs. The risk of infection by
drug-resistant HIV strains has increased year-
ly through the 1990s. "Super HAART" regi-
mens, consisting of four or more drugs, is
being used in patients for whom the existing
triple-cocktail therapy has failed. (Reuters,
5/3/01)
Non-Injection Drug Users at Risk for HCV
Non-injection drug users are at higher risk for
contracting HCV than members of the general
population, according to an National Institutes
of Health release.  The findings of a new study
report that 14% of non-injection drug using
women and 17% of non-injection drug using
men tested positive for HCV. This is signifi-
cantly higher than the 2% prevalence rate of
HCV among members of the general popula-
tion. Sharing of contaminated syringes in
injection drug use accounts for 60% of HCV
infections.  Researchers plan to look further
into the modes of HCV transmission to deter-
mine the risks associated with non-injection
drug use. (NIH  press release, 5/7/01)
Mortality Due to End-Stage Liver Disease
Increasing in HIV-Positive Patients
Although HAART has decreased HIV-related
mortality, end-stage liver disease is increasing
in importance as a comorbidity factor. One
study has shown that the percentage of deaths
of HIV-positive patients increased from 11.5%
in 1991 to 50% in 1998-1999. Most of these
patients had detectable antibodies to Hepatitis
C virus (HCV).  End-stage liver disease is now
the leading cause of death among HIV-positive
patients in the hospital in where this study was
conducted. (Clinical Infectious Diseases 32 (3):
492, 2/1/01.)
News Flashes
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through October 31, 2001. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. What is the first serological marker to appear in acute HBV
infection?
(a) HBc IgG
(b) HBsAb
(c) HBeAg
(d) HBsAg
(e) HbeAb
2. How does prior HIV infection affect the likelihood of 
establishing chronic HBV infection?
(a) it has no effect 
(b) it increases the chance of establishing chronic 
HBV infection
(c) it decreases the likelihood of establishing chronic 
HBV infection
(d) it increases the level of HBc IgM in the serum
(e) it decreases serum HBV DNA levels
3. What percentage of new HBV cases develop into chronic
HBV?
(a) 10%
(b) 20%
(c) 25%
(d) 50%
(e) 80%
4. What factors may be responsible for causing abnormal hepatic
transaminase levels?
(a) indinavir
(b) acute or chronic viral hepatitis infection
(c) isoniazid
(d) A and B
(e) A, B, C
5. Which of the following sensations should be tested during the
subjective portion of DSPN diagnosis?
(a) vibration
(b) light touch
(c) pain sensation
(d) thermal sensation
(e) all of the above
BROWN MEDICAL SCHOOL   OFFICE OF CONTINUING MEDICAL EDUCATION   BOX G-A2    PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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